21/07/201421/10/2023 Helix BioPharma Corp. Appoints New Independent Chair Of The Board admin 0 Comments
15/07/201421/10/2023 Helix BioPharma Corp Initiates Enrollment of Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 admin 0 Comments
07/07/201421/10/2023 Helix BioPharma Corp Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement admin 0 Comments
14/05/201421/10/2023 Helix BioPharma Corp Submits L-DOS47 Clinical Trial Application with Health Canada admin 0 Comments
22/04/201421/10/2023 Helix BioPharma Corp. Receives U.S. FDA Approval to Initiate a Clinical Trial of L-DOS47 admin 0 Comments
03/04/201421/10/2023 Helix BioPharma Corp. Submits L-DOS47 Investigational New Drug Application with U.S. Food and Drug Administration admin 0 Comments
11/03/201421/10/2023 Helix BioPharma Corp. Announces appointment of new director and observer to the Board of Directors admin 0 Comments